ClinicalTrials.gov
public full text
Public Domain
A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors
advanced-solid-tumorsbreast-cancerendometrial-cancerglioblastomahead-and-neck-squamous-cell-carcinomahnsccsarcoma
This is a Phase 1 dose-escalation study of PRT3645, a Cyclin-dependent Kinase 4/6 (CDK4/6) inhibitor, in patients with advanced or metastatic solid tumors. The purpose of this study is to investigate the safety, tolerability, dose limiting toxicity, and to determine maximally tolerated dose and recommended phase 2 dose to be used in subsequent development of PRT3645.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors#873682
- BRAF and MEK inhibitors rechallenge after an adverse drug reaction in patients with cancer: A pharmacovigilance cohort study#676789
- CDK4/6 Inhibitors in Patients With Hormone Receptor-positive Advanced Breast Cancer#904023
- CP-609,754 in Treating Patients With Advanced Solid Tumors#869888
- Clinical significance on switching CDK4/6 inhibitors among 13,284 patients with metastatic breast cancer#292640
Record · ID 832695
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive